Treatment Resistant Depression Market

Market Overview:

The 7 major treatment resistant depression markets reached a value of US$ 3,295.3 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6,286.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.05% during 2024-2034.

The treatment resistant depression market has been comprehensively analyzed in IMARC's new report titled "Treatment Resistant Depression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Treatment resistant depression refers to a type of depression that does not respond to at least two types of antidepressant medications. This condition results when the treatment drugs are ineffective in alleviating the symptoms of depression. People suffering from the illness may experience persistent feelings of sadness, hopelessness, and worthlessness, as well as other symptoms such as fatigue, changes in appetite and sleep patterns, difficulty concentrating, and a loss of interest in activities. The other common indications of the ailment include low energy and motivation, irritability, confusion, poor sexual drive, suicide ideation, etc. The diagnosis of treatment resistant depression mainly relies on a combination of the patient’s medical and psychiatric history, clinical features, and physical tests. The patient health questionnaire (PHQ) to measure and screen depressive symptoms is further utilized for disease diagnosis by healthcare professionals.

The rising cases of psychological issues, such as low motivation, poor adherence to treatment, high levels of stress, changes in brain chemistry, etc., are primarily driving the treatment resistant depression market. In addition to this, the increasing incidences of genetic and biological defects that result in delayed or no response to antidepressant drugs or other treatments are also propelling the market growth. Furthermore, the widespread adoption of augmentation therapy with synthetic thyroid hormone and mood-stabilizing drugs, which can improve recovery in patients, is creating a positive outlook for the market. Besides this, the emerging popularity of a non-invasive transcranial magnetic stimulation technique, since it utilizes electromagnetic pulses to regulate the neural function of brain structures associated with this condition, is also bolstering the market growth. Additionally, the inflating demand for cognitive behavioral therapy to potentially improve interpersonal skills by changing and identifying unhealthy thought patterns or emotions is acting as another significant growth-inducing factor. Moreover, the escalating application of esketamine nasal spray for disease treatment, owing to its numerous advantages including activation of neuroplasticity, enhancement of the brain’s ability to positively alter and grow, and improved outcomes in patients, is expected to drive the treatment resistant depression market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the treatment resistant depression market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for treatment resistant depression and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the treatment resistant depression market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the treatment resistant depression market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the treatment resistant depression market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current treatment resistant depression marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the treatment resistant depression market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the treatment resistant depression market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the treatment resistant depression market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of treatment resistant depression across the seven major markets?
• What is the number of prevalent cases (2018-2034) of treatment resistant depression by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of treatment resistant depression by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with treatment resistant depression across the seven major markets?
• What is the size of the treatment resistant depression patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of treatment resistant depression?
• What will be the growth rate of patients across the seven major markets?
   

Treatment Resistant Depression: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for treatment resistant depression drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the treatment resistant depression market?
• What are the key regulatory events related to the treatment resistant depression market?
• What is the structure of clinical trial landscape by status related to the treatment resistant depression market?
• What is the structure of clinical trial landscape by phase related to the treatment resistant depression market?
• What is the structure of clinical trial landscape by route of administration related to the treatment resistant depression market?